Skip to main navigation Skip to search Skip to main content

Disrupted uromodulin trafficking is rescued by targeting TMED cargo receptors

  • Silvana Bazua-Valenti
  • , Matthew R. Brown
  • , Jason Zavras
  • , Magdalena Riedl Khursigara
  • , Elizabeth Grinkevich
  • , Eriene Heidi Sidhom
  • , Keith H. Keller
  • , Matthew Racette
  • , Moran Dvela-Levitt
  • , Catarina Quintanova
  • , Hasan Demirci
  • , Sebastian Sewerin
  • , Alissa C. Goss
  • , John Lin
  • , Hyery Yoo
  • , Alvaro S. Vaca Jacome
  • , Malvina Papanastasiou
  • , Namrata Udeshi
  • , Steven A. Carr
  • , Nina Himmerkus
  • Markus Bleich, Kerim Mutig, Sebastian Bachmann, Jan Halbritter, Stanislav Kmoch, Martina Živná, Kendrah Kidd, Anthony J. Bleyer, Astrid Weins, Seth L. Alper, Jillian L. Shaw, Maria Kost-Alimova, Juan Lorenzo B. Pablo, Anna Greka
  • Broad Institute
  • Harvard University
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  • Kiel University
  • Charité – Universitätsmedizin Berlin
  • Free University of Berlin
  • Charles University
  • Wake Forest University

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The trafficking dynamics of uromodulin (UMOD), the most abundant protein in human urine, play a critical role in the pathogenesis of kidney disease. Monoallelic mutations in the UMOD gene cause autosomal dominant tubulointerstitial kidney disease (ADTKD-UMOD), an incurable genetic disorder that leads to kidney failure. The disease is caused by the intracellular entrapment of mutant UMOD in kidney epithelial cells, but the precise mechanisms mediating disrupted UMOD trafficking remain elusive. Here, we report that transmembrane Emp24 protein transport domain–containing (TMED) cargo receptors TMED2, TMED9, and TMED10 bind UMOD and regulate its trafficking along the secretory pathway. Pharmacological targeting of TMEDs in cells, in human kidney organoids derived from patients with ADTKD-UMOD, and in mutant-UMOD-knockin mice reduced intracellular accumulation of mutant UMOD and restored trafficking and localization of UMOD to the apical plasma membrane. In vivo, the TMED-targeted small molecule also mitigated ER stress and markers of kidney damage and fibrosis. Our work reveals TMED-targeting small molecules as a promising therapeutic strategy for kidney proteinopathies.

Original languageEnglish
Article numbere180347
Number of pages17
JournalJournal of Clinical Investigation
Volume134
Issue number24
DOIs
StatePublished - 16 Dec 2024

Bibliographical note

Publisher Copyright:
© 2024, Bazua-Valenti et al.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Disrupted uromodulin trafficking is rescued by targeting TMED cargo receptors'. Together they form a unique fingerprint.

Cite this